(Q44624962)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21703477%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

The future of inhaled antibiotic therapy. New products (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21703477%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21703477%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Montserrat Vendrell Relat

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21703477%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Gerard Muñoz Castro

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21703477%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Gladis Sabater Talaverano

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21703477%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

Spanish

0 references

publication date

1 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21703477%20AND%20SRC:MED&resulttype=core&format=json

Archivos de Bronconeumologia

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21703477%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

47 Suppl 6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21703477%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

30-32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21703477%20AND%20SRC:MED&resulttype=core&format=json

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

The effect of recombinant human lactoferrin on growth and the antibiotic susceptibility of the cystic fibrosis pathogen Burkholderia cepacia complex when cultured planktonically or as biofilms

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

New Antimicrobial Strategies in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0300-2896%2811%2970033-3

7 January 2021

10.1016/S0300-2896(11)70033-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21703477%20AND%20SRC:MED&resulttype=core&format=json

release_kthpwijt4zfdrlv7xbrxcajdfu

5 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kthpwijt4zfdrlv7xbrxcajdfu

24 November 2022

mapped directly with Wikidata item

1 reference